MD20140123A2 - Agenţi terapeutici optimizaţi pentru administrare subcutanată - Google Patents

Agenţi terapeutici optimizaţi pentru administrare subcutanată Download PDF

Info

Publication number
MD20140123A2
MD20140123A2 MD20140123A MD20140123A MD20140123A2 MD 20140123 A2 MD20140123 A2 MD 20140123A2 MD 20140123 A MD20140123 A MD 20140123A MD 20140123 A MD20140123 A MD 20140123A MD 20140123 A2 MD20140123 A2 MD 20140123A2
Authority
MD
Moldova
Prior art keywords
therapeutic agents
optimised
cmax
subcutaneous therapeutic
subcutaneous
Prior art date
Application number
MD20140123A
Other languages
English (en)
Romanian (ro)
Russian (ru)
Inventor
Уильям ГЕНРИ
Ричард ВОЛЬФ-ГАРРАУЭЙ
Джон Чарльз Майо
Майкл Джеймс Эрл
Original Assignee
Cantab Biopharmaceuticals Patents Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1206628.8A external-priority patent/GB201206628D0/en
Priority claimed from GBGB1213712.1A external-priority patent/GB201213712D0/en
Priority claimed from GBGB1214985.2A external-priority patent/GB201214985D0/en
Application filed by Cantab Biopharmaceuticals Patents Limited filed Critical Cantab Biopharmaceuticals Patents Limited
Publication of MD20140123A2 publication Critical patent/MD20140123A2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MD20140123A 2012-04-16 2013-04-16 Agenţi terapeutici optimizaţi pentru administrare subcutanată MD20140123A2 (ro)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1206628.8A GB201206628D0 (en) 2012-04-16 2012-04-16 Subcutaneous administration of PEGylated blood clotting factors
GBGB1213712.1A GB201213712D0 (en) 2012-08-01 2012-08-01 Modified therapeutic agents
GBGB1214985.2A GB201214985D0 (en) 2012-08-22 2012-08-22 Modified therapeutic agents
PCT/EP2013/057928 WO2013156488A2 (en) 2012-04-16 2013-04-16 Optimised subcutaneous therapeutic agents

Publications (1)

Publication Number Publication Date
MD20140123A2 true MD20140123A2 (ro) 2015-04-30

Family

ID=48190923

Family Applications (1)

Application Number Title Priority Date Filing Date
MD20140123A MD20140123A2 (ro) 2012-04-16 2013-04-16 Agenţi terapeutici optimizaţi pentru administrare subcutanată

Country Status (29)

Country Link
US (2) US20150086524A1 (OSRAM)
EP (1) EP2838566A2 (OSRAM)
JP (3) JP2015512927A (OSRAM)
KR (1) KR102137290B1 (OSRAM)
CN (1) CN104411335A (OSRAM)
AP (1) AP2014008049A0 (OSRAM)
AU (3) AU2013248296A1 (OSRAM)
BR (1) BR112014025737A2 (OSRAM)
CA (1) CA2869993C (OSRAM)
CL (1) CL2014002773A1 (OSRAM)
CO (1) CO7151496A2 (OSRAM)
CR (1) CR20140475A (OSRAM)
EA (1) EA033469B1 (OSRAM)
EC (1) ECSP14023048A (OSRAM)
GB (3) GB201910184D0 (OSRAM)
GE (1) GEP201706716B (OSRAM)
HK (1) HK1200695A1 (OSRAM)
IL (1) IL235129B (OSRAM)
IN (1) IN2014DN08598A (OSRAM)
MD (1) MD20140123A2 (OSRAM)
MX (2) MX2014012512A (OSRAM)
MY (1) MY190257A (OSRAM)
NI (1) NI201400122A (OSRAM)
NZ (1) NZ701205A (OSRAM)
PE (1) PE20150226A1 (OSRAM)
PH (1) PH12014502314B1 (OSRAM)
SG (1) SG11201406492YA (OSRAM)
WO (1) WO2013156488A2 (OSRAM)
ZA (1) ZA201407370B (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104073482A (zh) * 2013-12-30 2014-10-01 江苏众红生物工程创药研究院有限公司 聚乙二醇化的组织激肽释放酶及其制备方法和应用
GB201417589D0 (en) * 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
FR3034669B1 (fr) * 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
US20180169297A1 (en) * 2015-06-12 2018-06-21 Laboratoire Français Du Fractionnement Et Des Biotechnologies Injectable composition of factor vii and fillers
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
CN109998994B (zh) * 2018-02-13 2021-12-07 四川大学 包含药物的柔性脂质体及其制备方法
CN114929261A (zh) 2020-02-17 2022-08-19 生物测试股份公司 凝血因子viii的皮下施用
EP4138888A1 (en) * 2020-04-23 2023-03-01 Eli Lilly and Company Subcutaneous absorption and bioavailability of antibodies

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CH596313A5 (OSRAM) 1975-05-30 1978-03-15 Battelle Memorial Institute
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
WO1990015628A1 (en) * 1989-06-14 1990-12-27 Cetus Corporation Polymer/antibiotic conjugate
AU5098193A (en) 1992-09-01 1994-03-29 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
CA2145407C (en) 1992-09-28 2009-09-22 Louis A. Carpino New reagents for peptide couplings
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
JPH0892294A (ja) * 1994-09-29 1996-04-09 Teijin Ltd ヒト活性化プロテインｃ誘導体
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
CA2177644A1 (en) * 1995-05-31 1996-12-01 Peter D. Senter Polymeric prodrugs for beta-lactamase and uses thereof
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
ATE200030T1 (de) 1997-01-29 2001-04-15 Polymasc Pharmaceuticals Plc Pegylationsverfahren
AU2605099A (en) * 1998-02-25 1999-09-15 Micrologix Biotech, Inc. Indolicidin and cationic peptides conjugated with polymers
ATE428445T1 (de) * 2000-02-11 2009-05-15 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
ES2449224T3 (es) 2000-05-03 2014-03-18 Novo Nordisk Health Care Ag Administración subcutánea del Factor de coagulación VII
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
MXPA04012496A (es) * 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
UA86744C2 (en) * 2002-06-21 2009-05-25 Ново Нордиск Хэлс Кеа Аг Pegylated factor vii glycoforms
WO2004075923A2 (en) * 2003-02-26 2004-09-10 Nektar Therapeutics Al, Corporation Polymer-factor viii moiety conjugates
JP4698579B2 (ja) * 2003-04-08 2011-06-08 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 可逆的ｐｅｇ化薬物
US20130137157A1 (en) * 2003-04-09 2013-05-30 Novo Nordisk A/S Glycopegylated factor vii and factor viia
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
US20060198819A1 (en) 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
AU2005219090B2 (en) 2004-03-04 2008-01-10 Eisai R&D Management Co., Ltd Composition containing benzamidine derivative and method for stabilizing benzamidine derivative
AU2005260763B2 (en) * 2004-06-30 2011-12-22 Nektar Therapeutics Polymer-factor IX moiety conjugates
WO2006013202A2 (en) 2004-08-02 2006-02-09 Novo Nordisk Health Care Ag Conjugation of fvii
EP2975135A1 (en) 2005-05-25 2016-01-20 Novo Nordisk A/S Glycopegylated factor IX
EP2360170A3 (en) 2005-06-17 2012-03-28 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered proteins comprinsing at least one non-native cysteine
JP2009515508A (ja) * 2005-08-19 2009-04-16 ネオス テクノロジーズ インコーポレイテッド グリコｐｅｇ化因子ｖｉｉおよび因子ｖｉｉａ
KR20080108147A (ko) * 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
JP5570809B2 (ja) 2006-09-01 2014-08-13 ノボ ノルディスク ヘルス ケア アーゲー 修飾タンパク質
JP5876208B2 (ja) 2006-12-15 2016-03-02 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体
CA2671676C (en) * 2006-12-27 2014-04-22 Baxter Healthcare Sa Von willebrand factor-and factor viii-polymer conjugates having a releasable linkage
WO2008081024A1 (en) 2007-01-03 2008-07-10 Novo Nordisk Health Care Ag Subcutaneous administration of coagulation factor viia-related popypeptdes
WO2008119815A1 (en) * 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
KR20100016462A (ko) 2007-04-13 2010-02-12 카탈리스트 바이오사이언시즈, 인코포레이티드 변형 제ｖｉｉ 인자 폴리펩타이드 및 이의 용도
EP2014299A1 (en) 2007-07-11 2009-01-14 Novo Nordisk A/S Subcutaneous administration of coagulation factor VII
KR20100090684A (ko) 2007-10-09 2010-08-16 폴리테릭스 리미티드 신규한 접합 단백질 및 펩티드
CN101861335B (zh) 2007-10-16 2013-09-04 环状药物公司 凝血因子viia调节剂的制造、组合物和用途
EP2257311B1 (en) 2008-02-27 2014-04-16 Novo Nordisk A/S Conjugated factor viii molecules
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
EP2282767A4 (en) * 2008-04-16 2012-07-11 Bayer Healthcare Llc MODIFICATION OF FACTOR IX ORIENTED SITE
MX2010011672A (es) 2008-04-24 2011-03-02 Celtic Pharma Peg Ltd Conjugados del factor ix con vidas medias extendidas.
JP5642065B2 (ja) * 2008-05-23 2014-12-17 ノボ ノルディスク ヘルス ケア アーゲー ペグ化されたｇｌａ−ドメイン含有タンパク質を含む低粘度組成物
KR101763559B1 (ko) 2008-07-21 2017-08-14 폴리테릭스 리미티드 생물학적 분자의 컨쥬게이팅을 위한 신규한 시약 및 방법
JP4966434B2 (ja) * 2008-10-15 2012-07-04 バクスター・インターナショナル・インコーポレイテッド 結合抗体の存在下における組換え血液凝固因子のｐｅｇ化
HUE039906T2 (hu) * 2008-10-17 2019-02-28 Baxalta GmbH Alacsony fokú vízben oldható polimer tartalmú módosított vérfaktorok
WO2010083536A1 (en) * 2009-01-19 2010-07-22 Bayer Healthcare Llc Protein conjugate having an endopeptidase-cleavable bioprotective moiety
SG178141A1 (en) * 2009-07-27 2012-03-29 Baxter Int Blood coagulation protein conjugates
CN105524164A (zh) * 2010-02-16 2016-04-27 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
KR102229967B1 (ko) * 2010-07-30 2021-03-19 박스알타 인코퍼레이티드 옥심 결합용 친핵성 촉매
WO2012088123A1 (en) * 2010-12-22 2012-06-28 Nektar Therapeutics Polymer-factor vii moiety conjugates

Also Published As

Publication number Publication date
NI201400122A (es) 2016-12-02
JP2015512927A (ja) 2015-04-30
CL2014002773A1 (es) 2015-01-16
AU2013248296A1 (en) 2014-11-13
KR20140146171A (ko) 2014-12-24
KR102137290B1 (ko) 2020-07-23
IL235129B (en) 2022-06-01
IL235129A0 (en) 2014-12-31
GB2516388A (en) 2015-01-21
AU2020200842A1 (en) 2020-02-27
NZ701205A (en) 2016-02-26
MX2014012512A (es) 2015-01-15
JP2018024684A (ja) 2018-02-15
EA201491702A1 (ru) 2015-03-31
PH12014502314A1 (en) 2015-01-12
MY190257A (en) 2022-04-11
CR20140475A (es) 2015-01-23
EP2838566A2 (en) 2015-02-25
HK1200695A1 (en) 2015-08-14
ECSP14023048A (es) 2015-11-30
GB201418864D0 (en) 2014-12-03
GB201910184D0 (en) 2019-08-28
CO7151496A2 (es) 2014-12-29
AP2014008049A0 (en) 2014-11-30
BR112014025737A2 (pt) 2017-07-04
WO2013156488A3 (en) 2014-01-16
PE20150226A1 (es) 2015-02-14
WO2013156488A2 (en) 2013-10-24
ZA201407370B (en) 2017-09-27
AU2018200111B2 (en) 2019-11-07
US20180036229A1 (en) 2018-02-08
AU2018200111A1 (en) 2018-01-25
JP2019131593A (ja) 2019-08-08
IN2014DN08598A (OSRAM) 2015-05-22
US11351112B2 (en) 2022-06-07
MX2020014208A (es) 2021-03-09
PH12014502314B1 (en) 2020-01-31
GB201910190D0 (en) 2019-08-28
EA033469B1 (ru) 2019-10-31
CA2869993A1 (en) 2013-10-24
GEP201706716B (en) 2017-08-10
US20150086524A1 (en) 2015-03-26
SG11201406492YA (en) 2014-11-27
CA2869993C (en) 2023-05-23
JP6550107B2 (ja) 2019-07-24
CN104411335A (zh) 2015-03-11

Similar Documents

Publication Publication Date Title
MD20140123A2 (ro) Agenţi terapeutici optimizaţi pentru administrare subcutanată
MX2023000320A (es) Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion.
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
PH12015501067A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
MY166014A (en) Combination therapy methods for treating proliferative diseases
WO2012068531A3 (en) Novel compositions and uses of anti-hypertension agents for cancer therapy
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
UA108885C2 (uk) Композиція рисперидону для ін'єкційної депо-форми
MX358491B (es) Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
PH12014500386A1 (en) Combination treatment for hepatitis c
AU2016204185A1 (en) Methods of administering beta7 integrin antagonists
GB201200062D0 (en) Estradiol oromucosal liquid compositions
IN2015KN00005A (OSRAM)
MX2020012924A (es) Terapias combinadas de coenzima q10 para el tratamiento de cancer.
MX2021002633A (es) Dispersiones solidas de bendamustina e infusion continua.
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX341356B (es) Composiciones ciclopolisacárido anionico-catiónico y bendamustina.
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
PH12013502252B1 (en) Induction of il-12 using immunotherapy
UA111785C2 (uk) Композиція для лікування бородавок та спосіб лікування бородавок
MX2015004940A (es) Tratamiento de depresion y ptsd.
MY203919A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion